SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-008477
Filing Date
2020-05-13
Accepted
2020-05-13 15:14:44
Documents
45
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 557654
2 ex31-1.htm EX-31.1 18716
3 ex31-2.htm EX-31.2 18712
4 ex32.htm EX-32 8355
  Complete submission text file 0001493152-20-008477.txt   2019380

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE pvct-20200331.xml EX-101.INS 191007
6 XBRL SCHEMA FILE pvct-20200331.xsd EX-101.SCH 31407
7 XBRL CALCULATION FILE pvct-20200331_cal.xml EX-101.CAL 38678
8 XBRL DEFINITION FILE pvct-20200331_def.xml EX-101.DEF 92059
9 XBRL LABEL FILE pvct-20200331_lab.xml EX-101.LAB 191126
10 XBRL PRESENTATION FILE pvct-20200331_pre.xml EX-101.PRE 140857
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 20872801
SIC: 2834 Pharmaceutical Preparations